BridgeBio Pharma
company
About
BridgeBio Pharma focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D.
- 251 - 500
Details
- Last Funding Type
- Series D
- Last Funding Money Raised
- $299.20M
- Industries
- Biotechnology,Health Care,Life Science,Medical,Pharmaceutical
- Founded date
- Jan 1, 2014
- Number Of Employee
- 251 - 500
- Operating Status
- Active
BridgeBio is a biotechnology company that focuses on genetic disease therapies and develops those assets with the right approach in supporting R&D. BridgeBio creates a bridge from advancements in genetic science to patients with unmet needs via the entrepreneurial engine required to make life-changing medicines as rapidly as possible.BridgeBio's mission is to discover, create, test, and deliver transformative medicines to treat patients with genetic diseases.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
4
$474.20M
BridgeBio Pharma has raised a total of
$474.20M
in funding over 2 rounds. Their latest funding was raised on
Jan 23, 2019 from a Series D round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jan 23, 2019 | Series D | $299.20M | 3 |
Kohlberg Kravis Roberts
|
— | Detail |
| Sep 13, 2017 | Series C | $135M | 2 |
Kohlberg Kravis Roberts
|
— | Detail |
| May 1, 2017 | Series B | $33.10M | 1 |
Kohlberg Kravis Roberts
|
— | Detail |
| Mar 1, 2016 | Series B | $6.90M | 1 |
Kohlberg Kravis Roberts
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
4
4
BridgeBio Pharma is funded by 4 investors.
Kohlberg Kravis Roberts
and Sequoia Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Kohlberg Kravis Roberts
|
Yes | Series D |
Sequoia Capital
|
— | Series D |
Hercules Capital
|
— | Series D |
Janus Fund
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
